`
`Subject:
`
`Sent:
`
`Sent As:
`
`Attachments:
`
`BioElectronics Corporation (mkwhelan@verizon.net)
`
`U.S. TRADEMARK APPLICATION NO. 86222506 - ANTI-INFLAMMATORY VAC - N/A
`
`7/9/2014 4:54:57 PM
`
`ECOM119@USPTO.GOV
`
`Attachment - 1
`Attachment - 2
`Attachment - 3
`Attachment - 4
`Attachment - 5
`Attachment - 6
`Attachment - 7
`Attachment - 8
`Attachment - 9
`Attachment - 10
`Attachment - 11
`Attachment - 12
`Attachment - 13
`Attachment - 14
`Attachment - 15
`Attachment - 16
`Attachment - 17
`Attachment - 18
`Attachment - 19
`Attachment - 20
`Attachment - 21
`Attachment - 22
`Attachment - 23
`Attachment - 24
`Attachment - 25
`
`UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)
`OFFICE ACTION (OFFICIAL LETTER) ABOUT APPLICANT’S TRADEMARK APPLICATION
`
`86222506
`
`*86222506*
`
`CLICK HERE TO RESPOND TO THIS LETTER:
`http://www.uspto.gov/trademarks/teas/response_forms.jsp
`
`(cid:160) (cid:160)(cid:160)(cid:160) U.S. APPLICATION SERIAL NO.(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160) (cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160)(cid:160)(cid:160) MARK: ANTI-INFLAMMATORY VAC
`(cid:160)(cid:160) (cid:160)(cid:160) (cid:160)
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160) APPLICANT: BioElectronics Corporation
`(cid:160) (cid:160)(cid:160)(cid:160)(cid:160)(cid:160) CORRESPONDENT’S REFERENCE/DOCKET
`(cid:160)(cid:160)(cid:160)
`NO:(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160)(cid:160) CORRESPONDENT E-MAIL ADDRESS:(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`
`(cid:160)(cid:160)(cid:160) CORRESPONDENT ADDRESS:
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160) BIOELECTRONICS CORPORATION
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160) BIOELECTRONICS CORPORATION
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160)(cid:160)(cid:160) 4539 METROPOLITAN CT
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160)(cid:160)(cid:160) FREDERICK, MD 21704-9452
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`
`(cid:160) (cid:160) N/A
`
`(cid:160) (cid:160) mkwhelan@verizon.net
`
`
`
`OFFICE ACTION
`
`STRICT DEADLINE TO RESPOND TO THIS LETTER
`TO AVOID ABANDONMENT OF APPLICANT’S TRADEMARK APPLICATION, THE USPTO MUST RECEIVE APPLICANT’S
`COMPLETE RESPONSE TO THIS LETTER WITHIN 6 MONTHS OF THE ISSUE/MAILING DATE BELOW.
`
`(cid:160)I
`
`SSUE/MAILING DATE: 7/9/2014
`
`The referenced application has been reviewed by the assigned trademark examining attorney.(cid:160) Applicant must respond timely and completely to
`the issue(s) below.(cid:160) 15 U.S.C. §1062(b); 37 C.F.R. §§2.62(a), 2.65(a); TMEP §§711, 718.03.
`
`(cid:160)(cid:160)
`
`TEAS PLUS APPLICANTS – TO MAINTAIN REDUCED FEE, ADDITIONAL REQUIREMENTS MUST BE MET, INCLUDING
`SUBMITTING DOCUMENTS ONLINE:(cid:160) Applicants who filed their application online using the lower-fee TEAS Plus application form must
`(1) continue to submit certain documents online using TEAS, including responses to Office actions (see TMEP §819.02(b) for a complete list of
`these documents); (2) accept correspondence from the USPTO via e-mail throughout the examination process; and (3) maintain a valid e-mail
`address.(cid:160) See 37 C.F.R. §2.23(a)(1), (a)(2); TMEP §§819, 819.02(a).(cid:160) TEAS Plus applicants who do not meet these three requirements must
`submit an additional fee of $50 per international class of goods and/or services.(cid:160) 37 C.F.R. §2.6(a)(1)(iv); TMEP §819.04.(cid:160) However, in certain
`
`situations, authorizing an examiner’s amendment by telephone will not incur this additional fee. (cid:160)(cid:160)(cid:160)
`
`SUMMARY OF ISSUES that applicant must address:
`
`SECTION 2(d) REFUSAL – LIKELIHOOD OF CONFUSION
`DISCLAIMER REQUIRED
`IDENTIFICATION OF GOODS – AMEND TO AVOID DECEPTIVENESS
`
`SECTION 2(d) REFUSAL – LIKELIHOOD OF CONFUSION
`
`Registration of the applied-for mark ANTI-INFLAMMATORY VAC is refused because of a likelihood of confusion with the mark V.A.C. in
`U.S. Registration No. 1982349.(cid:160) Trademark Act Section 2(d), 15 U.S.C. §1052(d); see TMEP §§1207.01 et seq.(cid:160) See the enclosed registration.
`
`(cid:160)T
`
`rademark Act Section 2(d) bars registration of an applied-for mark that so resembles a registered mark that it is likely a potential consumer
`would be confused, mistaken, or deceived as to the source of the goods and/or services of the applicant and registrant.(cid:160) See 15 U.S.C. §1052(d).(cid:160)
`A determination of likelihood of confusion under Section 2(d) is made on a case-by case basis and the factors set forth in In re E. I. du Pont de
`Nemours & Co., 476 F.2d 1357, 177 USPQ 563 (C.C.P.A. 1973) aid in this determination.(cid:160) Citigroup Inc. v. Capital City Bank Grp., Inc., 637
`F.3d 1344, 1349, 98 USPQ2d 1253, 1256 (Fed. Cir. 2011) (citing On-Line Careline, Inc. v. Am. Online, Inc., 229 F.3d 1080, 1085, 56 USPQ2d
`1471, 1474 (Fed. Cir. 2000)).(cid:160) Not all the du Pont factors, however, are necessarily relevant or of equal weight, and any one of the factors may
`control in a given case, depending upon the evidence of record.(cid:160) Citigroup Inc. v. Capital City Bank Grp., Inc., 637 F.3d at 1355, 98 USPQ2d at
`1260; In re Majestic Distilling Co., 315 F.3d 1311, 1315, 65 USPQ2d 1201, 1204 (Fed. Cir. 2003); see In re E. I. du Pont de Nemours & Co., 476
`F.2d at 1361-62, 177 USPQ at 567.
`
`(cid:160)I
`
`n this case, the following factors are the most relevant:(cid:160) similarity of the marks, similarity and nature of the goods, and similarity of the trade
`channels of the goods.(cid:160) See In re Viterra Inc., 671 F.3d 1358, 1361-62, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012); In re Dakin’s Miniatures Inc. ,
`59 USPQ2d 1593, 1595-96 (TTAB 1999); TMEP §§1207.01 et seq.
`
`(cid:160)T
`
`he overriding concern is not only to prevent buyer confusion as to the source of the goods and/or services, but to protect the registrant from
`adverse commercial impact due to use of a similar mark by a newcomer.(cid:160) See In re Shell Oil Co., 992 F.2d 1204, 1208, 26 USPQ2d 1687, 1690
`(Fed. Cir. 1993).(cid:160) Therefore, any doubt regarding a likelihood of confusion determination is resolved in favor of the registrant.(cid:160) TMEP
`§1207.01(d)(i); see Hewlett-Packard Co. v. Packard Press, Inc., 281 F.3d 1261, 1265, 62 USPQ2d 1001, 1003 (Fed. Cir. 2002); In re Hyper
`Shoppes (Ohio), Inc., 837 F.2d 463, 464-65, 6 USPQ2d 1025, 1026 (Fed. Cir. 1988).
`
`COMPARISON OF MARKS(cid:160)
`The applicant’s mark is ANTI-INFLAMMATORY VAC.
`
`(cid:160)T
`
`he registered mark is V.A.C.
`
`(cid:160)
`(cid:160)(cid:160)(cid:160)
`(cid:160)
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160)
`(cid:160)
`
`
`The registered mark and the “VAC” portion of the applied-for mark are essentially phonetic equivalents and thus sound similar. (cid:160) Similarity in
`sound alone may be sufficient to support a finding that the marks are confusingly similar.(cid:160) In re White Swan Ltd., 8 USPQ2d 1534, 1535 (TTAB
`1988); see In re 1st USA Realty Prof’ls, Inc. , 84 USPQ2d 1581, 1586 (TTAB 2007); TMEP §1207.01(b)(iv).
`
`Although marks are compared in their entireties, one feature of a mark may be more significant or dominant in creating a commercial
`impression.(cid:160) See In re Viterra Inc., 671 F.3d 1358, 1362, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012); In re Nat’l Data Corp. , 753 F.2d 1056,
`1058, 224 USPQ 749, 751 (Fed. Cir. 1985); TMEP §1207.01(b)(viii), (c)(ii).(cid:160) Matter that is descriptive of or generic for an applicant’s goods
`and/or services is typically less significant or less dominant in relation to other wording in a mark.(cid:160) See In re Chatam Int’l Inc. , 380 F.3d 1340,
`1342-43, 71 USPQ2d 1944, 1946 (Fed. Cir. 2004); In re Binion, 93 USPQ2d 1531, 1534 (TTAB 2009).
`
`(cid:160)I
`
`n the present case, the attached evidence shows that the wording “ ANTI-INFLAMMATORY” in the applied-for mark is merely descriptive of
`or generic for applicant’s goods that are used to reduce inflammation. (cid:160) Thus, this wording is less significant in terms of affecting the mark’s
`commercial impression, and renders the wording “VAC” the more dominant element of the mark.
`
`(cid:160)A
`
`dding a term to a registered mark generally does not obviate the similarity between the compared marks, as in the present case, nor does it
`overcome a likelihood of confusion under Section 2(d).(cid:160) See Coca-Cola Bottling Co. v. Jos. E. Seagram & Sons, Inc., 526 F.2d 556, 557, 188
`USPQ 105, 106 (C.C.P.A. 1975) (finding BENGAL and BENGAL LANCER and design confusingly similar); In re Toshiba Med. Sys. Corp., 91
`USPQ2d 1266, 1269 (TTAB 2009) (finding TITAN and VANTAGE TITAN confusingly similar); In re El Torito Rests., Inc., 9 USPQ2d 2002,
`2004 (TTAB 1988) (finding MACHO and MACHO COMBOS confusingly similar); TMEP §1207.01(b)(iii).(cid:160) In the present case, the VAC and
`V.A.C.(cid:160) portions of the marks are nearly identical.(cid:160) Therefore the addition of the descriptive wording “ANTI-INFLAMMATORY” does not
`obviate the similarity of the marks.
`
`(cid:160)I
`
`n these respects, the literal portions of the applicant’s mark and that of the registrant are highly similar in appearance, sound, connotation and
`commercial impression, and therefore, are likely to cause confusion as to the origin of the goods.
`
`(cid:160)C
`
`OMPARISON OF GOODS
`The applicant’s goods are identified as “Low frequency electromagnetic therapy apparatus” (cid:160) The goods named in the registration
`comprise/include “medical devices, namely pump units for promoting wound healing, receptacles for collecting wound drainage, and parts and
`
`accessories for the foregoing.” (cid:160)(cid:160)
`
`The goods and/or services of the parties need not be identical or even competitive to find a likelihood of confusion.(cid:160) See On-line Careline Inc. v.
`Am. Online Inc., 229 F.3d 1080, 1086, 56 USPQ2d 1471, 1475 (Fed. Cir. 2000); Recot, Inc. v. Becton, 214 F.3d 1322, 1329, 54 USPQ2d 1894,
`1898 (Fed. Cir. 2000) (“[E]ven if the goods in question are different from, and thus not related to, one another in kind, the same goods can be
`
`related in the mind of the consuming public as to the origin of the goods.”); TMEP §1207.01(a)(i). (cid:160)(cid:160)
`
`The respective goods and/or services need only be “related in some manner and/or if the circumstances surrounding their marketing [be] such
`that they could give rise to the mistaken belief that [the goods and/or services] emanate from the same source.” (cid:160) Coach Servs., Inc. v. Triumph
`Learning LLC, 668 F.3d 1356, 1369, 101 USPQ2d 1713, 1722 (Fed. Cir. 2012) (quoting 7-Eleven Inc. v. Wechsler, 83 USPQ2d 1715, 1724
`(TTAB 2007)); Gen. Mills Inc. v. Fage Dairy Processing Indus. SA, 100 USPQ2d 1584, 1597 (TTAB 2011); TMEP §1207.01(a)(i). (cid:160)(cid:160) In this case,
`it is enough that applicant’s goods and registrant’s goods are both used to promote healing.
`
`(cid:160)T
`
`he attached Internet evidence consists of excerpts about therapy devices for use in the field of wound healing.(cid:160) This evidence establishes that
`the applicant’s goods and registrant’s goods are similar or complementary in terms of purpose or function.
`(cid:160) Therefore, applicant’s and
`registrant’s goods and/or services are considered related for likelihood of confusion purposes. (cid:160) See, e.g., In re Davey Prods. Pty Ltd., 92 USPQ2d
`1198, 1202-04 (TTAB 2009); In re Toshiba Med. Sys. Corp., 91 USPQ2d 1266, 1268-69, 1271-72 (TTAB 2009).
`
`(cid:160)E
`
`vidence obtained from the Internet may be used to support a determination under Trademark Act Section 2(d) that goods and/or services are
`related.(cid:160) See, e.g., In re G.B.I. Tile & Stone, Inc., 92 USPQ2d 1366, 1371 (TTAB 2009); In re Paper Doll Promotions, Inc., 84 USPQ2d 1660,
`1668 (TTAB 2007).
`
`(cid:160)T
`
`he marks are used to identify medical devices for use in the field of healing.(cid:160) The same consumers will be exposed to the therapeutic products
`identified with the marks.(cid:160) The similarities among the marks and the goods of the parties are so great as to create a likelihood of confusion.
`
`CONCLUSION
`Accordingly, in view of the closely related nature of the goods of the parties and the strong similarity of the marks and their commercial
`impressions, confusion as to the source of the goods is likely under Section 2(d) of the Trademark Act.
`
`(cid:160)A
`
`lthough the examining attorney has refused registration, the applicant may respond to the refusal to register by submitting evidence and
`arguments in support of registration.(cid:160) If the applicant chooses to respond to the refusal to register, the applicant must also respond to the
`
`(cid:160)(cid:160)
`(cid:160)(cid:160)
`
`
`following.
`
`DISCLAIMER REQUIRED
`Applicant must disclaim the wording “ ANTI-INFLAMMATORY” because it merely describes an ingredient, quality, characteristic, function,
`feature, purpose, or use of applicant’s goods and/or services, and thus is an unregistrable component of the mark. (cid:160) See 15 U.S.C. §§1052(e)(1),
`1056(a); DuoProSS Meditech Corp. v. Inviro Med. Devices, Ltd., 695 F.3d 1247, 1251, 103 USPQ2d 1753, 1755 (Fed. Cir. 2012) (quoting In re
`
`Oppedahl & Larson LLP, 373 F.3d 1171, 1173, 71 USPQ2d 1370, 1371 (Fed. Cir. 2004)); TMEP §§1213, 1213.03(a).(cid:160)(cid:160)
`
`The attached evidence from online dictionaries shows this wording means “ used to reduce inflammation” and “counteracting or suppressing
`inflammation.” Therefore, the wording merely describes applicant’s therapeutic devices that reduce inflammation.
`
`(cid:160)A
`
`n applicant may not claim exclusive rights to terms that others may need to use to describe their goods and/or services in the marketplace.(cid:160) See
`Dena Corp. v. Belvedere Int’l, Inc. , 950 F.2d 1555, 1560, 21 USPQ2d 1047, 1051 (Fed. Cir. 1991); In re Aug. Storck KG, 218 USPQ 823, 825
`(TTAB 1983).(cid:160) A disclaimer of unregistrable matter does not affect the appearance of the mark; that is, a disclaimer does not physically remove
`the disclaimed matter from the mark.(cid:160) See Schwarzkopf v. John H. Breck, Inc., 340 F.2d 978, 978, 144 USPQ 433, 433 (C.C.P.A. 1965); TMEP
`
`§1213.(cid:160)(cid:160)
`
`If applicant does not provide the required disclaimer, the USPTO may refuse to register the entire mark.(cid:160) See In re Stereotaxis Inc., 429 F.3d
`1039, 1040-41, 77 USPQ2d 1087, 1088-89 (Fed. Cir. 2005); TMEP §1213.01(b).
`
`(cid:160)A
`
`pplicant should submit a disclaimer in the following standardized format:
`
`No claim is made to the exclusive right to use “ANTI-INFLAMMATORY” apart from the mark as shown.
`
`(cid:160)F
`
`or an overview of disclaimers and instructions on how to satisfy this disclaimer requirement online using the Trademark Electronic Application
`System (TEAS) form, please go to http://www.uspto.gov/trademarks/law/disclaimer.jsp.
`
`IDENTIFICATION OF GOODS – AMEND TO AVOID DECEPTIVENESS
`The use or intended use of the applied-for mark on goods that do not in fact have or exhibit anti-inflammatory properties is or will be deceptive.(cid:160)
`See TMEP §1203.02-.02(b).(cid:160) To avoid a deceptiveness refusal, applicant must amend the identification to indicate that the goods possess this
`relevant feature or characteristic.(cid:160) See TMEP §§1203.02(e)(ii), (f)(i), 1402.05 et seq.(cid:160) Merely amending the identification to exclude goods or
`services with the named feature or characteristic will not avoid a deceptiveness refusal.(cid:160) TMEP §1203.02(f)(i).
`
`(cid:160)T
`
`herefore, applicant must amend the identification to the following, if accurate:(cid:160)(cid:160)
`
`Class 10: Low frequency electromagnetic therapy apparatus for reducing or suppressing inflammation
`
`(cid:160)A
`
`n applicant may only amend an identification to clarify or limit the goods and/or services, but not to add to or broaden the scope of the goods
`and/or services.(cid:160) 37 C.F.R. §2.71(a); see TMEP §§1402.06 et seq., 1402.07.
`
`RESPONSE GUIDELINES(cid:160)
`To expedite prosecution of the application, applicant is encouraged to file its response to this Office action online via the Trademark Electronic
`Application System (TEAS), which is available at http://www.uspto.gov/trademarks/teas/index.jsp.(cid:160) If applicant has technical questions about the
`TEAS response to Office action form, applicant can review the electronic filing tips available online at
`http://www.uspto.gov/trademarks/teas/e_filing_tips.jsp and email technical questions to TEAS@uspto.gov.
`
`(cid:160)I
`
`f applicant has questions regarding this Office action, please telephone or e-mail the assigned trademark examining attorney.(cid:160) All relevant e-
`mail communications will be placed in the official application record; however, an e-mail communication will not be accepted as a response to
`this Office action and will not extend the deadline for filing a proper response.(cid:160) See 37 C.F.R. §2.191; TMEP §§304.01-.02, 709.04-.05.(cid:160) Further,
`although the trademark examining attorney may provide additional explanation pertaining to the refusal(s) and/or requirement(s) in this Office
`action, the trademark examining attorney may not provide legal advice or statements about applicant’s rights. (cid:160) See TMEP §§705.02, 709.06.
`
`(cid:160)(cid:160)
`(cid:160)
`(cid:160)(cid:160)
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`
`
`/John M. C. Kelly/
`United States Patent and Trademark Office
`Trademark Examining Attorney
`Law Office 119
`571-272-9412
`john.kelly@uspto.gov
`
`(cid:160)(cid:160)(cid:160)
`
`TO RESPOND TO THIS LETTER: (cid:160) Go to http://www.uspto.gov/trademarks/teas/response_forms.jsp. (cid:160) Please wait 48-72 hours from the
`issue/mailing date before using the Trademark Electronic Application System (TEAS), to allow for necessary system updates of the application.(cid:160)
`For technical assistance with online forms, e-mail TEAS@uspto.gov.(cid:160) For questions about the Office action itself, please contact the assigned
`trademark examining attorney.(cid:160) E-mail communications will not be accepted as responses to Office actions; therefore, do not respond to
`this Office action by e-mail.
`
`(cid:160)A
`
`ll informal e-mail communications relevant to this application will be placed in the official application record.
`
`(cid:160)W
`
`HO MUST SIGN THE RESPONSE:(cid:160) It must be personally signed by an individual applicant or someone with legal authority to bind an
`applicant (i.e., a corporate officer, a general partner, all joint applicants).(cid:160) If an applicant is represented by an attorney, the attorney must sign the
`
`response.(cid:160)(cid:160)
`PERIODICALLY CHECK THE STATUS OF THE APPLICATION: (cid:160) To ensure that applicant does not miss crucial deadlines or official
`notices, check the status of the application every three to four months using the Trademark Status and Document Retrieval (TSDR) system at
`http://tsdr.uspto.gov/. (cid:160) Please keep a copy of the TSDR status screen. (cid:160) If the status shows no change for more than six months, contact the
`Trademark Assistance Center by e-mail at TrademarkAssistanceCenter@uspto.gov or call 1-800-786-9199. (cid:160) For more information on checking
`status, see http://www.uspto.gov/trademarks/process/status/.
`
`(cid:160)T
`
`O UPDATE CORRESPONDENCE/E-MAIL ADDRESS:(cid:160) Use the TEAS form at http://www.uspto.gov/trademarks/teas/correspondence.jsp.
`
`(cid:160)(cid:160)
`
`
`mun //mEdIEa\—dH:|\EIrIar
`
`thefreeduzllunar cum/amunflammalur
`
`DE/19/2EI14 12 33 D5 PM
`
`2 ammammmw
`[—infIam’eboré]
`
`Elymulngy: Gk‘ arm i L, fnflammara, In sel afire
`1 Dana
`g In a substance or procedure max counlemnls or re:uses mnainmauon
`2 an armlnflzmmalory dmg
`Mwws Mama! uimnew. aw. edmIm.E1flW.E\s:vI=r.
`
`Page
`' 0" III
`ewoiu arawsei
`
`i|=.xT I IE3P‘fi'L¥I'—J
` —- F Th2FreeDicIinnzry f‘ Gougle F Bing
`Em"
`HIEWEEDICHDNARY rm Seaucll
`"““"""“
`35' @
`l_RanunDe<Me new
`1,
`F‘ Ward/Arllcle F startswiu: “ Ends wllh ‘‘ Text
`6 559,939 524 vismmsaewea
`ewe
`
`I Dictionary: Jlnesaums
`
`I Encyciopenia I wixipenu:encvcwllenia
`_ ll ___
`
`
`
`ant nflammatory Aismimain:uicuonammesaums_vimmma
`
`Pllgelouls
`I :T
`—Ad D G
`
`
`CVIE / Hnk E3
`Share 1 Bar
`in
`E Son
`E3 PMS’ mend
`S Y 0°95
`D
`"Jig/ ii“
`“"“Y "‘*‘°“E"1 °€"‘--
`amiinflammatoty fan 1i in-flam-ma-Iu ryl [—ln—€|am'ah4DV"e)v:nuEI|e1aEI\rIg or suppvessing inflammaliun; also, an agent Ihal 5» acts
`M umvmm mm
`DDl‘IViSMEd\El‘D\IIK\wl1filYfDfH(lMhCun§|lmEf§ em: I?! Sanndgrs, an imwirll D1 E\§:wai Wm AH rights rsenad.
`Prev-iemn-run Tue-mam
`furA\IPi|1erlls rm om
`Mme TEI‘h‘1\
`
`
`
`Feedback
`iii».
`
`
`
`
`
`V‘
`’ E3
`
`‘DR
`Share
`
`flgfigféku ”"' 3‘
`, »,
`,
`
`.,
`
`P
`
`
`
`
`
`
`1. cuumerztlmg ur supplessing innmwumuu
`mm antiinllammaiory [an"|e—in—nam’aMar—e]
`Samsung
`2. an agent mail so acts
`Gafaxy S“4
`|lH|Ev—K£:naEnnynlnpaflm and mmmm Madmna Nursing nmlAmen Hash): smnm Eaman,a2nu:| u,s...mm_ Ill vmprmlnl Elsamnr, mu NIIWME rzewufl
`Active‘ ' wAIcH LIVE JUNE an s 29 ‘‘
`AT :3: DDPIVI E'I' D8591
`........;
`amiinllammatory,
`‘
`adj/n serves Ia reheve infiammatiau in cases, such as injury or infeclron; beneficial trail ofsome e55en!i2\ DHS
`/lav/eI\\savv.:nl(Eafl Danna’? Manse Ian: Knnwl
`Jana: Mushy‘; uiam»,Iflflnmiflemgulavymi MlanntmeMeduwe in ms, Elsaaer
`My hunkinaiiis
`Piease M at regisiem use Immiams You
`can also lug M with Faceimok, Gnagle, Twiller,
`
`
`4 .9,
`an-Qj-in-[lam-ma-ta-ry (3
`Reducing infiamlnalion by acnng an body respunses, wimoumiiecuy amagonzing me causative agent denouiig agenls such as glucoconiculds and aspirin.
`nm em. Mam! Du£mnavy§Far\u zm:
`
`
`
`
`an-1.i-in-llam-ma-to-ry (ar|'
`in—fia
`mg)
`Reducing inflaminaiinn y ac ng on
`y respnnsas‘ winimudiiecciy antagonizing lhe causative agent denmiiig agenls such as glumcnflicnlds and aspirin
`Ma1uz\DIx1mrIarvfnl lha mam PIMLEVWIE sun Nursmu e Fanex zmz
`
`“__n
`
`
`
`
`mun //madlflairdllziltlrlar
`
`See Mler delulis
`sliup Now
`‘"0’
`‘‘’‘’‘”5’
`
`,__,
`é
`
` Aiivsnlsemem laud banner?
`Please lel usmaw;
`
`lnelreeuieliunar earn/anliinflarninalur
`Ella/la/2El14 12 33 D5 PM
`wieinau iaimmiynrime rieam Prurgeunaariu lmrslifl e Faflex zuiz
`
`an-Ii-in-flam-ma-to-ry (aniein4iam'a—riire)
`Reducing irillaininaliimriy
`iespunses, wnnnu:direeny anlagonizing me nausanve agenr; derlonrlg agents such as glllcnmnicnlfls and aspii-in
`
`Mailmi u.a......aa.u.. am »...m...;er..i 1iI12
`
`Patient discussion about amiinfiammatory.
`I1. Can anyone sllggesl a ireaurienuur plantar fast us, Ipzrtlmln Illlrasnund, pllysin, aniunlianirnaiory agenls? My lrienii has has Piamar Fasciilisformnre irian 1 year and has pelsevemd wilh all lhe ususal lrealmenls
`above plus leis ol res: imrn welght-bunny and eleuzrliull
`A. Padded fool spllnls. silicone lieels insen and special shoes (e g. arch-suppofllng shoes] may also nelp. rl-iese are usually sold and med by a pralessianal. Eiercise is another lmpclrlam measure. Some paiienis zienem iroln
`avu ing walking lxarellxrl er in sleepers mi rauier using slrues fninl inefirsi s1ep
`Mare advanced Inedlnlellln iricluile :|2ruil]-Iulzel arreeilreiiue iineeilinre, bu|u|illulu IllXilI(L4Y!1i|dI Iu IJu|ux) IlIjuI:|iulI: and slulyely.
`The prognosis is usually favorable, and mast iianams achieve ieliei iifrlie pain.
`However. all uiuie above isJust zar general knowledge — ifyou nave ally speeini: quesnun, you may warn in lmnsull a uaclor
`veu may mad rue-re nere
`wwwrllm nihglwvlmedlhep|u5len:ylaIIit}el[|D7fl21 lrlin
`Read more or ask a guesliari aboul aniiinuammzlagg
`rneamrerriisrumaes uyuuieuixmsmqgamimmrmerneogmmummmemmemuuurimmmmim uremaemmieuymeae nnlflmlms
`
`Wan] lnuianlr TFD far im eJrisIellt9’I Tell a friend auairl us. add a Ink lnuiis page ur \/Ell me webmasters gage ror free fun conlerll.
`link In iliis page:
`<3 hZ:f='httDl//lIled1¢:al—
`»
`dx:t1:lna:y.theExeed1ztinnnty.can/nnti1nE)nlmnnta:y'>nnt1
`1nf]anlmaCnIy(/B)
`
`Please hmikmark wml sucial rn
`
`
`
`yaurvmes are noticed and appreclaledi
`
`Ii.-carve
`
`i
`
`MyrbeLriq is a prescripllan medicine
`{or adults used to (reel overscrive
`bladder (GAB) with symptoms o[
`urgency, frequency, and leakage.
`
`¥iIyri:e|m}' innraaegreni my muse wsurblurm
`Dr:-sswt-mlrlcra
`euvmihsynuvhl-andDrussurs
`\\':VSE ir mu have .1 nisiary at man uiuaa pressure ii
`is rt-ninrrlmeriiit-d mar laur iizlzlar mm Ilwur hklnfl
`Drrsswe willie yau an-Iaivlng Mirhelrlil Mrrueiria
`
`/4dvclLl3cnIcn|(Bnfl rmnnerv mam lctu: lmuw)
`
` FeedyuIlr brain feed a riungg Child
`
`— Mentioned in
`
`
`
`— References in periodicals archive
`renenliy ieeaned me resulls or a pnpuIallan—based_ c:§e4:Dmm| study regarding nskfaniars for pedlamr:
`invasive group A slrepluccunal (GAS) irrieciioli (1 1, noung mat ille 'new" use urnansieraiilal uniimlarnmamiy
`
`— Medical browser
`
`
`
`— Full browser
`. milluluul
`e ai..i..uu,
`. nnfllflvvlllrln fl1Ih'lflIWlHflH\!
`
`
`
`mun //m2dIcaLdn:hnnar
`
`thefreeduzlltmar cum/amunflammalur
`
`DE/19/2EI1412 33 D5 PM
`
`—|flfEn
`ivumyiamxgconicasiemne
`aremelacm
`
`Atela
`ghen
`aremsahcyllc acid
`AHFEHDCDNIEOSIBIIXUS
`Akehia gumala
`an wnflzmmalo 1
`an rflflalnlnam 1 3 enls
`aim-rnflammam 1 dlug
`Amklnflammalng thug:
`amimnammarag agents
`amimnammareg drug
`amilnllammatey Ieukalriene
`Amwheumatic Drugs
`Ascnplin
`asplnn
`
`drugs (Nsmns), defined a; nsmn use Q week; befme diagnosis, was assocmen wim Ilwaslve (ms infection,
`whems sell-defined "regular NSAID usewa5 not
`Nonstemidar anfllnflammalflydmgg and gmugfii snegromaaa/ , by Mulla Zuber E /Emegfng Fnfectious
`Diseases
`Instead, dlug tumpznies hzu/9 tnntenttmed on 2-,:pivv\, ihupmren, cyzlmnxyganzsig inhibitors, and ulnar
`anliinflammatnry dings man blcmka single biochemical palhllay but don't plnlecl EH5
`Running mterielence fresh aggmach to fighting lnflammallon by Segga N /Science News
`More results »
`
`l1>
`
` anlllmmlme
`anlllnfechall wlamlll
`anlllnfeclwe
`amllrrfccfivl: dmg
`> allliinfiummllory
`anllmllammala [2 ents
`anliinflammalau drug
`anliinflammalau leukouiene
`anlllnluhllat cuagutsnl complex
`anlnnitnatm
`anlllnsulln
`armkenutman
`anllkelugenesls
`anllkelugenir:
`Antikickbzck Lzw
`
`
`AdChn£ma
`
`o annnmmge auluanfibudy
`I zrmlmmune
`an Mac an vivamln
`anhlnfechve
`
`0 anhlnfechve drug
`.A.. nfinmalulm No Ealnmwden
`> almlllllammamry
`o armmllammam agent
`a armmllammam agent
`I antiinflammai agenl
`0 zntiinflammai agenl
`o anmnflammagy agenl
`o znnnnflammam agents
`0 zrmlnflalllmafi drug
`I annlnllalllluafl drug
`a armmnammam drug
`. anninnammam harmanen
`
`<
`
`\/
`
`H Set sail In your
`Snrvllung -6: xy 5 4
`laundry room.
`‘G I.TE Cl Flinn: .
`
`> :v|x(k.(:I:]l on
`8499"“
`* win: new2-yur enmm
`
`
`
`um Aaguflw
`Mwemsementtfiud mnnerr Please we:us mm
`
`_ «’-' Tl|eFreeDinion|ry 4‘ Goagle
`\,/(2%
`""vREE N“[ seam.
`5‘ Wmvd]Ar|i:|e -" smriswini F Ends mm ‘‘ Texl
`
`W
`Furs:-fag:Free1oulnnr1.2:na1muug|wmumIneDgy|Bzsubaunnkifi
`Free T°°'5
`rnn.a....m.. Fin:-imfia1II|.1nhm\ I|lL7ubIa¢Ick|malc\|g 0%‘.
`MtleSIe|Ta1lux1lke|P1iw3c[g:[\Faeflbsck|Aavu\\§ewihUs|(2np;ryItI2n14F.IE1( mi
`uigmiiiu
`an Wm... m|flIrs|vdIfl3av(lud\r1Qd'>mnl1i'Yr$§i|IvIfi4 Via-arum gazgraphu. and mu mtuenizaaa isiw
`wamanmau-w§unn.1I.is.immaii...si..Janmmmss:a5my1muu»=amandsm
`imaiaadiu be mi ‘in vbanfa ias'vm..suum,o. am .4 i|=+;i|i mam, w anv wawgssmax.
`
`
`
`mun //www nxfurddlctwunavxes cum/us/definumu/amerman 2nI1\IsH/anmnflammatuv
`EIE/19/201412 3419 PM
`
`l°"9"°9°'"°”°“
`. OxfordDIchonarIes
`
`Dlcunnary
`
`FRENCH
`
`GERMAN
`
`ITALIAN
`
` Type a word 0!’ phrase
`
`ENGUSH
`E-ynon_vn15
`
`SPANISH
`Grammal
`
`EN
`
`\U.‘S\
`
`Definificu uf 11Im'—x'nfi'ammamry m English:
`
`anti-inflammatory
`Syllabificatiun: an-n—in-flaxn-ma-wry
`Pronun:1atmn: /,ancéin‘aama,tiu—é, ,anfi—
`/
`
`ADJEC'I1VE
`
`(Chiefly Df a dmg) used to reduce inflammation,
`MORE EXAMPLE SENTENCES
`
`Fmriautn re
`
`NOLIM [plural anti"-inflalznnalnries)
`
`An an!i—>nflamma1ory drug.
`MORE EXAMPLE SENTENCES
`
`Back :0 mp
`
`~
`
`MORE ONA.NT|—|'NFLAI‘IMATOR‘{
`
`Nearby W0rds
`
`€
`
`
`mun //www uxfurddictiunaiies cum/us/defimiinn/amerman Bnuiish/anii—inflamma|ui
`EIE/19/201412 3419 PM
`
`MUM: tXAMPLi: S|:Ni l:Nl.'tS
`
`\t
`
`More definitions ofanti-inflammatory
`
`Definition of anti-inflammatory in:
`- The British & World English dictionary
`
`anIi—g
`antmnfeciive
`anfi-inflammatory
`
`a””"”‘e"ed“5‘
`Anti-Lebanon Mountains
`
`More words in this
`category
`
`ampneiamine
`antichulinergic
`anxiolvtic
`arsphenamine
`bactericide
`
`Translate ami-
`inflammatory
`
`ink) Italian
`
`‘
`‘M: or THE DA!’
`
`
`
`
`mm:/mwuxfurdmmnnanas cum/u idafinrfiuvv/smsrman enrfllsh/anh—mflEmma4urV'
`DE/1522011112 SW19 PM
`
`F'mnunr.\at|Dn, fmuzé
`
`ADJECTNE
`
`scruffy and n g\ecIed m anpearante
`
`
`
`
`
`Print: Jul 9, 2D14
`
`T4-E76320
`
`TYPED DRAWING
`
`Serial Number
`T46T632O
`
`Status
`REGISTERED AND RENEWED
`
`Word Mark
`v.A.c.
`
`Standard Character Merit
`No
`
`Registration Number
`;9e2349
`
`Date Registered
`;99sxOsx25
`
`Type of Marin
`TRADEMARK
`
`Register
`DR:NcIDAL
`
`Mark Drawing Code
`[1
`TYPED DRAWING
`
`Owner
`KO: LICENSING,
`TEXAS T82492248
`
`INO. OORRORATION DELAWARE 12930 IH—IO West San Antonio
`
`Goodsfservioes
`Class Status —— ACTIVE.
`
`IC 010.
`
`Us
`
`U26 U39 044.
`
`G 6: 3: medical
`
`devices, namely pump units for promoting wound healing, receptacles
`for collecting wound drainage, and parts and accessories for the
`foregoing. First Use:
`l995HU4fUl. First Use In Commerce:
`l995fU4fUl.
`
`Filing Date
`l995fU5fGl
`
`Examining Attorney
`WARD.
`JOYCE A.
`
`Attorney of Record
`Pamela B. Hu”
`
`
`
`Pfini:JuI9,2D14
`
`75874141
`
`DESIGN MARK
`
`Serial Number
`T58T4l4l
`
`Status
`REGISTERED AND RENEWED
`
`Word Mark
`NAODDN ASSISTED OLOSDRE
`
`Standard Character Merit
`No
`
`Registration Number
`2557555
`
`Date Registered
`2OO2x12x1O
`
`Type Of Marl:
`TRADEMARK
`
`Register
`DR:NcIDAL
`
`Mark Drawing Code
`[1
`TYPED DRAWING
`
`Owner
`Kc: Licensing, Inc. OORSORATION DELAWARE 12930 IH—IO West San Antonio
`TEXAS T82492248
`
`Goodsfserviees
`[ medical
`G & S:
`U26 U39 044.
`US
`IC 010.
`Class Status -- ACTIVE.
`devices, namely, pump units for promoting Wound healing, receptacles
`for collecting wound drainage, and parts and accessories for the
`foregoing ]
`* parts and accessories for pump units for promoting Wound
`healing and receptacles for collecting wound drainage*. First Use:
`l995/Odfifll. First Use In Commerce:
`l995fO4fOl.
`
`Disclaimer Statement
`NO OLAIN IS MADE TO THE EXCLUSIVE RIGHT TO USE "VAODDN ASSISTED" ASART
`FROM THE MRRK AS SHOWN.
`
`Filing Date
`l999Hl2Hl5
`
`Examining Attorney
`SNARE, TINA L.
`
`
`
`Print: Jul 9, 2D14
`
`T587-II-141
`
`Attorney of Record
`Pamela B. Huff
`
`
`
`
`
`mun //www ream/er Ix I:u/I2!rmcaHessarch/chrurrrowuundsf
`
`EI7/EIBJQIJM DA 33 59 PM
`
`RECOVER
`
`
`Clinimlly Prawn Median! Therapy far MeHim! Pmfessinrmlx
`
`carom
`
`Iacnnanogy
`
`Apmlmalxnns
`
`cumml Research
`
`uq
`
`Pronucns
`
`In me man:
`
`Dlslrilmlurs
`
`amvacn
`
`Chronic Wounds
`
`RecoveryRx® Chronic Wound Studies
`
`Introduction
`Low—Leve| Pulsea Rauzolreouency Frerds and ms Treatment of solflossue rnrunes
`The arm nnms remure Is In mmrne me mam nrrysmrngrcar nrncesses mvnlwen rmrre nealrrrg mwnurrns armm suggest a mechanism my wnrcn nursen
`ramuvreuuerrw (RF) er-reruvr unrre currents rrrauuea In ussues Mme aunrrcalrurr urmaterrergy. mawrrlruerrce ns Cuurse
`Emnrrasrs Is grven to me can maven my enema rrr rrmmrung ma Drncesses mwounn nearrng Relerence rs mane m the gmwrng evruenne mat nursed RFenargy
`sums me trme cuurse ulwuurru rrearrrrg and me nyumnesrs Is urunuseamat one nussrme mecrremsm uy wrrrcrr nursen RF energy accererates wound rrealrrrg rs
`by remmng enema
`
`Purseu ramurrerzuerrcy eremrurrragrretr: new
`merapy rs zvarrams m varrnus rurms Extarrsrve
`crrnrcar research has been conducted wrm a
`
`BioEIactronlcs Medlcal Device Chronlc Wound Recuvary
`nueeeare Fnol Ulcer Fallen!
`
`View(lomplele punnsnea Paper
`
`
`
`mun //www ream/er 7:4 cu/errnneewesearerrterrrunrewuunusfl
`
`mw
`
`'
`
`
`
`EI7/EIBJQIZH4 DA 33 59 PM
`Umma: researcu was ueerr uuuuuueuWm H
`rarge numner er cumica: pumrcanons rm rrardIn
`heal and mronrc wounds Mass researm
`however‘ has been dune mm dewces mat use
`relanvelymgtl power‘ are rarge and cums
`based Trrese Lrrerapres have been srrmwrr tn
`be evfectrve rmtdue some iveuuenny emre
`enmrmmrrs (ummme dauyvman mrnlnrrae
`nmued prxemrar nu wulesplead use
`ReczweryR>@Iecmlology rs are mlmaxunzamun
`am-recmaruunar lame emuumemusedm
`h06DI|a!5 and cumcs Amarrces rn rrucmelemorrrcs have made rl possrme to dehvei me c11n|:a|\y amen and 511nevmr emended durauon trrerarmn smaH
`covrvemem andcos|—e1fe<.'uve apwcauons
`Recrwerykmcs anmled tumewomld. Incovouratmgmlo me dressmgor on low onrre dressing fx>r241u:ws per day The radmnerxuency emuromagneuc field wom
`Recoverymoa passes mmugh me dvessrng, Ineveible, me device dues nolneedto ne m mrea conlaamnm me snrr, ms makes for aswnpre apprrmnran unnrs
`Dowerful Ieohnologyr whrar rm: oniy Drolnotes wound heafing but also reduces mmmc wmmd Dain
`Vuumrumrusesuufiesmichinnlmen-fieutsuimunmssiashumensuiuxeticnloersmmuloerslrmnvymemnuanurermaaun
`Published Case Series
`m a case senes anew pauerns we were treatedwrm Reccweryamau Temple rum and Anne CJmIc‘Pm1aIlel|)n1a‘aiH7!e pauenls rradmng standing mcels mau
`rradvaned preumus meqapres rrre slutty penodwas srx ween: T